Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL)- evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1750
https://www.valueinhealthjournal.com/article/S1098-3015(15)01807-0/fulltext
Title :
Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL)- evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01807-0&doi=10.1016/j.jval.2015.03.1750
First page :
A300
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
1237